Pieris Pharmaceuticals Inc represents values of innovation, dedication, and excellence in the pharmaceutical industry. As a biotechnology company, Pieris Pharma focuses on advancing novel targeted protein therapeutics to improve patients' lives. Committed to scientific expertise and cutting-edge technology, Pieris Pharma strives to develop innovative solutions for various diseases such as cancer, respiratory disorders, and rare genetic conditions. With a strong corporate philosophy centered around collaboration, integrity, and patient-centricity, Pieris Pharma aims to revolutionize the field of therapeutic protein engineering and make a positive impact on global healthcare.

Pieris Pharmaceuticals Inc is primarily present in the United States, Germany, and Switzerland.

Pieris Pharmaceuticals Inc has achieved several significant milestones in its journey. The company successfully entered into multiple strategic collaborations, including partnerships with top pharmaceutical companies, which has enhanced its research and development capabilities. Pieris Pharmaceuticals Inc also obtained regulatory approvals for clinical trials, demonstrating the progress in its innovative therapies. The company's accomplishments include securing investments and grants, validating its potential in the biopharmaceutical industry. Pieris Pharmaceuticals Inc has consistently delivered positive clinical results and progressed its pipeline of candidates, strengthening its position as a leading player in the field. These achievements highlight the company's dedication to advancing novel therapeutics and its commitment to drive growth and value.

Pieris Pharmaceuticals Inc is a renowned company that specializes in the development and commercialization of innovative therapies. Founded in 2001, Pieris Pharmaceuticals has a rich history of pioneering advancements in the field of biotechnology. The company is dedicated to addressing unmet medical needs and improving patient outcomes through its proprietary Anticalin® technology platform. With a focus on therapeutic areas like oncology, respiratory diseases, and other severe conditions, Pieris Pharmaceuticals continues to forge partnerships and collaborations with leading industry players to bring its groundbreaking drugs to the market. This company's commitment to research, innovation, and the pursuit of scientific excellence has solidified its position as a frontrunner in the pharmaceutical industry.

The main competitors of Pieris Pharmaceuticals Inc in the market include companies such as AstraZeneca, Amgen, Novartis, and Roche.

Pieris Pharmaceuticals Inc is primarily active in the biotechnology industry.

The business model of Pieris Pharmaceuticals Inc focuses on the development and commercialization of innovative anticalin-based therapeutics. As a clinical-stage biotechnology company, Pieris Pharmaceuticals utilizes its proprietary Anticalin platform to create next-generation protein therapeutics for a wide range of diseases. The company collaborates with pharmaceutical partners to advance its drug candidates and expand their reach in various therapeutic areas, including oncology, respiratory diseases, and immuno-oncology. By leveraging its unique technology, Pieris Pharmaceuticals aims to provide targeted treatment options that address unmet medical needs and improve patient outcomes.

Az Pieris Pharmaceuticals P/E mutatója -76,65.

Az Pieris Pharmaceuticals KUV 3,05.

Az AlleAktien Minőségi Score Pieris Pharmaceuticals esetében 3/10.

A várt Pieris Pharmaceuticals forgalma 6,76 Mió. USD.

A(z) várt Pieris Pharmaceuticals nyereség -269 280,02 USD.

Pieris Pharmaceuticals Inc was founded in 2001 in Freising, Germany. The company operates in the biopharmaceutical industry and develops innovative therapeutics based on the Anticalin technology. The Anticalin technology is a patented platform technology used to develop highly specific and effective medications. The company is headquartered in Boston, Massachusetts and has offices in Europe. Pieris Pharmaceuticals is listed on the NASDAQ stock exchange and had a revenue of over 35 million US dollars in 2020. The company has over 200 employees and focuses on the development of therapeutics for the treatment of cancer and inflammation. The company divides its business model into four main areas: 1. Research and development 2. Partnerships and licenses 3. Product sales and license fees 4. Financing Research and development: Pieris Pharmaceuticals specializes in developing medications for the treatment of cancer and inflammation. The company uses its patented Anticalin technology to develop therapeutic agents that provide a treatment option for patients who do not respond to conventional treatment methods, due to their high specificity and effectiveness. The company is engaged in the identification and development of new drug candidates, which are then tested in various phases of clinical trials. Pieris Pharmaceuticals currently has several promising drug candidates in development. Partnerships and licenses: Pieris Pharmaceuticals seeks partnerships with other companies and research institutions to advance the research and development of Anticalin-based therapeutics. The company has already formed several partnerships with major pharmaceutical companies such as Servier, Roche, Daiichi Sankyo, and AstraZeneca. Pieris Pharmaceuticals also grants licenses to other companies to enable their use of the Anticalin technology. These partnerships and licenses expand the market for the Anticalin technology and contribute to the further development of Anticalin-based therapeutics. Product sales and license fees: Pieris Pharmaceuticals has agreements with other companies for the marketing of its products. The medications developed by the company are licensed to these companies for distribution. Pieris Pharmaceuticals receives license fees from these companies based on product sales. Financing: Pieris Pharmaceuticals finances its research and development of therapeutics through the sale of stocks, private investors, and proceeds from partnerships and license fees. The company has successfully completed several funding rounds and raised additional funds to support the research and development of therapies. Conclusion: Pieris Pharmaceuticals' business model brings the patented Anticalin technology to market for the development of specific, effective therapeutics for the treatment of cancer and inflammation. The company focuses on sharing its expertise and technology with other companies to provide additional resources and expand the market for Anticalin-based therapeutics. Through successful financing of research and development activities, the company has added several drug candidates to its pipeline.

A(z) Pieris Pharmaceuticals évente alkalommal oszt ki 0 USD összegű osztalékot.

A Pieris Pharmaceuticals esetében jelenleg nem lehet kiszámítani a osztalékot, vagy a vállalat nem fizet osztalékot.

A(z) Pieris Pharmaceuticals ISIN kódja: US7207951036.

A Pieris Pharmaceuticals WKN-je A12G4Q.

Az Pieris Pharmaceuticals tőzsdei rövidítése PIRS.

Az elmúlt 12 hónapban a(z) Pieris Pharmaceuticals osztalékot fizetett összegben. Ez körülbelül osztalékhozamnak felel meg. A következő 12 hóban a(z) Pieris Pharmaceuticals várhatóan 0 USD összegű osztalékot fog fizetni.

A(z) Pieris Pharmaceuticals jelenlegi osztalékhozama .

A(z) Pieris Pharmaceuticals negyedévente fizet osztalékot. Az osztalékokat a következő hónapokban osztják ki: .

A Pieris Pharmaceuticals az elmúlt 0 évben minden évben fizetett osztalékot.

A következő 12 hónapban 0 USD összegű osztalékra számítanak. Ez 0 % osztalékhozamnak felel meg.

A(z) Pieris Pharmaceuticals a(z) 'Egészség' szektorhoz van besorolva.

Az utolsó, Pieris Pharmaceuticals által 2024. 08. 27.-án/én fizetett 0 USD összegű osztalék megszerzéséhez a részvénynek az ex-nap előtti 2024. 08. 27.-nál kellett lennie a portfóliódban.

Az utolsó osztalék kifizetése 2024. 08. 27. időpontban történt.

2023 évben a Pieris Pharmaceuticals 0 USD összegű osztalékot fizetett ki.

Az Pieris Pharmaceuticals osztalékait USD fizeti ki.